Amcad Biomed (ROCO:4188) Total Equity: NT$600.82 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4188 Amcad Biomed Corp ROCO:4188
53 GF Score
Price NT$9.45
GF Value NT$9.10
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Amcad Biomed Total Equity?

Amcad Biomed ROCO:4188 -0.32% 53 Total Equity is NT$600.82 Mil as of Dec. 2025. GuruFocus rates ROCO:4188 with a GF Score™ of 53/100 and a GF Value™ of NT$9.10 (Fairly Valued). The stock has 4 warning signs investors should review.

Amcad Biomed's total equity for the quarter that ended in Dec. 2025 was NT$600.82 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Amcad Biomed Total Equity Historical Data

* Premium members only.

The historical data trend for Amcad Biomed's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amcad Biomed Total Equity Chart

Amcad Biomed Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 579.03 519.78 477.95 663.72 600.82

Amcad Biomed Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 663.72 639.37 619.41 608.83 600.82
ROCO:4188
53GF Score
Amcad Biomed Corp ROCO:4188
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amcad Biomed Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Amcad Biomed's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=622.703-21.882
=600.82

Amcad Biomed's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=622.703-21.882
=600.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of NT$600.82 Mil mean?
Amcad Biomed (ROCO:4188) has a Total Equity of NT$600.82 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Amcad Biomed and its competitors.
Is Amcad Biomed's Total Equity too high?
Amcad Biomed's current Total Equity is NT$600.82 Mil. Overall, Amcad Biomed has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Amcad Biomed's Total Equity compare to ABT and SYK?
Amcad Biomed's Total Equity of NT$600.82 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Devices & Instruments company?
A good Total Equity depends on the Medical Devices & Instruments industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Amcad Biomed and its competitors. Amcad Biomed's current Total Equity is NT$600.82 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amcad Biomed stock overvalued right now?
Based on GuruFocus' analysis, Amcad Biomed (ROCO:4188) is currently considered Fairly Valued. The stock's GF Value™ is NT$9.10, compared to a current price of NT$9.45 — trading 3.8% above its estimated fair value. The current Total Equity is NT$600.82 Mil. Amcad Biomed's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Amcad Biomed (ROCO:4188), the current Total Equity is NT$600.82 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amcad Biomed (ROCO:4188) Overvalued in 2026?

Based on GuruFocus' analysis, Amcad Biomed stock appears to be overvalued. The current stock price of NT$9.45 is trading 3.8% above its estimated GF Value™ of NT$9.10. GuruFocus considers Amcad Biomed to be Fairly Valued.

Key valuation signals for ROCO:4188:

  • Total Equity: NT$600.82 Mil
  • GF Value™: NT$9.10 vs. price of NT$9.45 (3.8% above fair value)
  • GF Score™: 53/100 with 4 warning signs

No single metric tells the full story. See the ROCO:4188 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amcad Biomed Business Description

Address Fuxing N. Road, No. 167, 5th Floor, Zhongshan District, Taipei, TWN, 104
Amcad Biomed Corp develops computer-aided detection and diagnosis(CADe/CADx) software devices. Its product pipeline includes AmCAD-UT Detection, AmCAD-UV, AmCAD and AmCAD-UO. Geographically, the company generates revenue from Taiwan, China, Europe, Asia (excluding Taiwan and China), and other countries, out of which the majority of the revenue is generated from Taiwan. The company has two segments: the Medical Diagnostic Software segment, which is responsible for the development and sales of smart medical imaging diagnostic software devices, and the Precision Medical Equipment segment, which is responsible for research, development, manufacturing, and sales of high-end ultrasonic probes. The company generates the majority of its revenue from the Precision Medical Equipment segment.
53GF Score

Get the complete analysis for ROCO:4188

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$9.45
Price
NT$9.10
GF Value